Translating Breakthrough Academic Science Into Venture-Ready Biotech
Nova BioVentures works hands-on with scientific founders to build investor-ready biotech companies — reducing development risk and accelerating time to value.
Assessing fundability, mapping the development path to clinical proof of concept, and designing a capital strategy — before institutional investors enter
Hands-on executive leadership from company formation through seed round — owning strategy, operations, investor relations, and pharma partnerships
A trusted global network of early-stage investors, VCs, and pharma players to accelerate syndication and open strategic partnership opportunities
A Transformative Moment in Biotech
The pace of scientific discovery and early-stage investment is accelerating worldwide, creating new opportunities to translate academic innovation into venture-backed biotech companies.
Pace of
Innovation
for Early-Stage
Investment
for Early-Stage
CEOs
An Engine for Early Biotech Value Creation
Nova BioVentures works hands-on with scientific founders to build investor-ready biotech companies with reduced development risk and higher value creation through early proof-of-concept focus.
Scientific & Strategic De-risking
- Early fundability assessment across modality and indication
- Development roadmap to clinical proof of concept
- Capital planning and financial strategy design
Hands-on Company Building
- Strategic leadership and operational execution for early-stage companies
- Development partner identification and selection
- Represents company externally as interim CEO
inflection points
Capital & Partner Access
- Strategic access to early-stage investors to support pre-seed round financing
- Trusted global network of VC and pharma players for later rounds and partnership opportunities
The Nova Partnership
Nova doesn’t consult — we are hands-on co-pilots partnering with scientific founders for 12–18 months to support spin-out creation, providing hands-on executive leadership through the seed round and advisory support through exit.
Validation
Leadership
Advisor
Nova BioVentures
Nova BioVentures is an early-stage biotech venture builder founded by Nicole Clarke, PhD, MBA, MSM. Nicole has worked across the entire value generation chain in drug development — from discovery to post-market support — and brings the totality of that expertise to Nova.
As CEO of an immuno-oncology spin-out, Nicole raised over €6M in seed capital, negotiated asset technology transfer, defined the company’s development roadmap, and built its operating foundation from inception.
Nicole has led cross-functional teams responsible for immuno-oncology assets and targeted therapies from Phase I through Phase III. She has also consulted hospital and health system executives on care delivery and worked in transaction advisory for the biotech and pharmaceutical sector.
Nicole holds a PhD in Cancer Biology and Master of Science in Medicine from Stanford University School of Medicine, a Bachelor of Science in Chemical Engineering from Princeton University, and an Executive MBA from IESE Business School.
Ready to Build Something Exceptional?
Whether you’re a TTO, academic founder, or early-stage investor — let’s talk about how Nova can help translate your science into value.
